Diflucan®
Fluconazole · oral tablet
Antifungal
Approved uses
Vaginal candidiasis, oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and prophylaxis of candidiasis in bone marrow transplantation patients who receive cytotoxic chemotherapy and/or radiation therapy
Vaginal candidiasis 150 mg as a single oral dose. Oropharyngeal candidiasis 200 mg on the first day, then 100 mg once daily for at least 2 weeks. Esophageal candidiasis 200 mg on the first day, then 100 mg once daily (up to 400 mg/day by response) for a minimum of three weeks and at least two weeks after symptoms resolve. Cryptococcal meningitis 400 mg on the first day, then 200 mg once daily (400 mg once daily by response) for 10 to 12 weeks after the cerebrospinal fluid becomes culture negative; 200 mg once daily for suppression of relapse in AIDS. Bone marrow transplant prophylaxis 400 mg once daily; patients anticipated to have severe granulocytopenia (less than 500 neutrophils cells/mm 3) should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 1000 cells/mm 3.
OFF-LABELNot in the FDA label for this product
Candida chorioretinitis and endophthalmitis
Loading dose 800 mg (12 mg/kg), then 400 to 800 mg (6 to 12 mg/kg) once daily for at least 4 to 6 weeks, with final duration set by resolution of the lesions.
Guideline · low-quality data
The IDSA candidiasis guideline recommends this regimen for fluconazole-susceptible isolates in chorioretinitis with or without vitritis, and grades both as a strong recommendation on low-quality evidence. With vitritis the same systemic regimen is given plus intravitreal amphotericin B deoxycholate 5 to 10 mcg/0.1 mL sterile water or voriconazole, and vitrectomy is considered. The label's tissue penetration table lists no ocular compartment; the supporting ocular pharmacokinetics come from a rabbit study in which aqueous and vitreous concentrations were at least 70% of serum in non-inflamed eyes, not from human data.
Contraindications
- Hypersensitivity to fluconazole or to any of its excipients
- Coadministration of other drugs known to prolong the QT interval and are metabolized by CYP3A4, such as erythromycin, pimozide and quinidine
Tablets 50, 100, 200 mg (bottles of 30; 100 and 200 mg also unit dose 100); 150 mg unit dose 1; suspension 350 or 1400 mg per 35 mL bottle
Triazole antifungal; highly selective inhibitor of the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, so lanosterol is not converted to ergosterol and 14-alpha-methyl sterols accumulate, which may account for the fungistatic effect. Labeled activity covers most isolates of Candida albicans, C. parapsilosis, C. tropicalis, C. glabrata (many isolates only intermediately susceptible) and Cryptococcus neoformans; C. krusei should be considered resistant, and no filamentous fungus appears on the label's activity list.
Warnings & Precautions
- Hepatic injury: Use caution in liver dysfunction. Rare serious hepatotoxicity has occurred, including fatalities primarily in patients with serious underlying medical conditions, with no obvious relationship to total daily dose, duration, sex or age; it has usually, but not always, been reversible on discontinuation. Monitor patients with abnormal liver function tests for more severe injury; discontinue if clinical signs and symptoms consistent with liver disease develop that may be attributable to the drug.
- Anaphylaxis: In rare cases, anaphylaxis has been reported.
- Exfoliative skin disorders: Fatal outcomes reported in patients with serious underlying disease; in deep seated fungal infection monitor any rash closely and stop the drug if lesions progress, and in superficial fungal infection stop it for a rash that may be attributed to the drug.
- Potential for fetal harm: Case reports describe a pattern of distinct congenital anomalies after high dose maternal fluconazole (400 to 800 mg/day) during most or all of the first trimester; if the drug is used in pregnancy or the patient becomes pregnant while taking the drug, inform her of the potential hazard to the fetus. Effective contraceptive measures should be considered in women of child-bearing potential on 400 to 800 mg/day, through treatment and for approximately 1 week after the final dose.
- Spontaneous abortion and congenital abnormalities: Epidemiological studies suggest a potential risk with 150 mg as a single or repeated dose in the first trimester, but these studies have limitations and the findings have not been confirmed in controlled clinical trials.
- QT prolongation: Fluconazole causes QT prolongation via inhibition of the rectifier potassium channel current (Ikr), and rare post-marketing cases of torsade de pointes have occurred, mostly in seriously ill patients with multiple confounding risk factors. Hypokalemia and advanced cardiac failure raise the risk of life-threatening ventricular arrhythmias and torsade de pointes, so administer with caution in these conditions. Avoid the combination with erythromycin.
- Renal dysfunction: Administer with caution; for multiple doses give 50% of the daily dose when creatinine clearance is 50 mL/min or less without dialysis.
- Adrenal insufficiency: Reported in patients receiving azoles, including fluconazole, and reversible cases have been reported with fluconazole. Patients on long-term fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued.
- Dizziness or seizures: These may occasionally occur, which should be taken into account when driving vehicles or operating machines.
- Non-albicans superinfection: Superinfection with Candida species that are often inherently not susceptible, for example C. krusei, may require an alternative antifungal.
- Higher incidence of drug related adverse events: Weigh the convenience and efficacy of the single oral dose for vaginal yeast infections against a higher incidence of drug related adverse events than with intravaginal agents (26% versus 16%) in U.S. comparative clinical studies.
- Increased plasma concentration: Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor and a strong CYP2C19 inhibitor, so coadministered compounds metabolized by these enzymes risk increased plasma concentration; use caution and monitor carefully, including for adverse reactions to narrow therapeutic window drugs. The enzyme inhibiting effect persists 4 to 5 days after discontinuation because of the long half-life. Avoid concomitant abrocitinib, lemborexant and voriconazole.
- Myopathy and rhabdomyolysis: Risk increases with HMG-CoA reductase inhibitors metabolized through CYP3A4 (atorvastatin, simvastatin) or CYP2C9 (fluvastatin). If concomitant therapy is necessary, observe for symptoms and monitor creatine kinase; discontinue the statin if a marked increase is observed or myopathy or rhabdomyolysis is diagnosed or suspected. Dose reduction of statins may be needed.
- Hypoglycemia: Clinically significant hypoglycemia may be precipitated with oral hypoglycemic agents, and one fatality has been reported with glyburide. Fluconazole raises tolbutamide, glyburide and glipizide concentrations; with these or other sulfonylureas, monitor blood glucose carefully and adjust the sulfonylurea dose as necessary.
- Bleeding events: Prothrombin time may increase with coumarin-type anticoagulants, and post-marketing bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria and melena) have been reported with prothrombin time increases on warfarin. Monitor prothrombin time carefully; warfarin dose adjustment may be necessary.
- Uveitis: Reported in patients given fluconazole with rifabutin, and there have been reports of rifabutin serum levels increased up to 80%; monitor these patients carefully.
- Cross-hypersensitivity: No data on cross-hypersensitivity with other azoles; prescribe with caution in patients hypersensitive to another azole.
- Malabsorption and sucrase-isomaltase deficiency: The powder for oral suspension contains sucrose and should not be used in patients with hereditary fructose, glucose/galactose malabsorption, and sucrase-isomaltase deficiency.
Common Side Effects
With one 150 mg dose for vaginal candidiasis, the commonest treatment-related events were headache (13%), nausea (7%) and abdominal pain (6%), and diarrhea (3%), dyspepsia (1%), dizziness (1%) and taste perversion (1%) also occurred; possibly related side effects reached 26% versus 16% on comparators. Over 7 or more days in 4048 patients, treatment-related events of 1% or more were nausea 3.7%, headache 1.9%, skin rash 1.8%, vomiting 1.7%, abdominal pain 1.7% and diarrhea 1.5%. In 577 pediatric patients the commonest were vomiting (5%), abdominal pain (3%), nausea (2%) and diarrhea (2%). Rare serious hepatic reactions, including fatalities, have occurred; transaminases exceeded 8 times the upper limit of normal in about 1% in trials. Post-marketing reports add QT prolongation, torsade de pointes, seizures, exfoliative skin disorders, rare anaphylaxis, leukopenia and thrombocytopenia.
Pregnancy: Avoid except in severe or potentially life-threatening fungal infection where the anticipated benefit outweighs the possible risk to the fetus. Case reports describe a rare distinctive pattern of birth defects, brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis and congenital heart disease, in infants exposed to 400 to 800 mg daily through most or all of the first trimester. Retrospective epidemiological studies suggest a potential risk of spontaneous abortion and congenital abnormality after single or repeated 150 mg first-trimester doses, unconfirmed in controlled trials.
Lactation: Present in milk at low levels. After a single 150 mg dose in 10 breastfeeding women the estimated daily infant dose was 0.39 mg/kg/day, about 13% of the labeled pediatric maintenance dose, and a published survey of 96 women taking 150 mg every other day reported no serious adverse reactions in infants. No data after repeated or high-dose use; exercise caution.
Shown effective for oropharyngeal candidiasis in patients 6 months to 13 years. Use for esophageal candidiasis, systemic Candida infections and cryptococcal meningitis is supported by adult efficacy and small noncomparative pediatric studies, with limited data for primary treatment of cryptococcal meningitis. Safety and effectiveness for prophylaxis in premature infants weighing less than 750 grams at birth have not been established, and intestinal perforation was more frequent than with placebo. A 35 mg/kg loading dose is recommended in pediatric patients on ECMO.